HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation

Overview

Journal Brain Sci

Publisher MDPI

Date 2021 Oct 23

PMID 34679364

Citations 100

Authors

Joanna Mikulska

Gabriela Juszczyk

Monika Gawronska-Grzywacz

Mariola Herbet

Affiliations

Soon will be listed here.

Abstract

The hypothalamic-pituitary-adrenal (HPA) axis is involved in the pathophysiology of many neuropsychiatric disorders. Increased HPA axis activity can be observed during chronic stress, which plays a key role in the pathophysiology of depression. Overactivity of the HPA axis occurs in major depressive disorder (MDD), leading to cognitive dysfunction and reduced mood. There is also a correlation between the HPA axis activation and gut microbiota, which has a significant impact on the development of MDD. It is believed that the gut microbiota can influence the HPA axis function through the activity of cytokines, prostaglandins, or bacterial antigens of various microbial species. The activity of the HPA axis in schizophrenia varies and depends mainly on the severity of the disease. This review summarizes the involvement of the HPA axis in the pathogenesis of neuropsychiatric disorders, focusing on major depression and schizophrenia, and highlights a possible correlation between these conditions. Although many effective antidepressants are available, a large proportion of patients do not respond to initial treatment. This review also discusses new therapeutic strategies that affect the HPA axis, such as glucocorticoid receptor (GR) antagonists, vasopressin V1B receptor antagonists and non-psychoactive CB1 receptor agonists in depression and/or schizophrenia.

Citing Articles

Effect of Treatment on Steroidome in Women with Multiple Sclerosis.

Hill M, Kancheva R, Velikova M, Kanceva L, Vcelak J, Ampapa R Int J Mol Sci. 2025; 26(5).

PMID: 40076462 PMC: 11899614. DOI: 10.3390/ijms26051835.

The Impact of Seasonality on Mental Health Disorders: A Narrative Review and Extension of the Immunoseasonal Theory.

Modzelewski S, Naumowicz M, Suprunowicz M, Oracz A, Waszkiewicz N J Clin Med. 2025; 14(4).

PMID: 40004649 PMC: 11856923. DOI: 10.3390/jcm14041119.

The neuroscience in breast cancer: Current insights and clinical opportunities.

Wang J, Wang M, Jiang L, Lin N Heliyon. 2025; 11(3):e42293.

PMID: 39975839 PMC: 11835589. DOI: 10.1016/j.heliyon.2025.e42293.

Bibliometric insights into astrocytic roles in depression and treatment.

Lin L, Guo Z, Ren Z, Feng Y, Fang P, Wang T Front Cell Neurosci. 2025; 18:1521398.

PMID: 39882216 PMC: 11775634. DOI: 10.3389/fncel.2024.1521398.

Neurotensin via Type I Receptor Modulates the Endotoxemia Induced Oxido-Inflammatory Stress on the Sympathetic Adrenomedullary System of Mice Regulating NF-κβ/Nor-Epinephrine Pathway.

Tiwari A, Mohanty B Cell Biochem Biophys. 2025; .

PMID: 39881060 DOI: 10.1007/s12013-025-01679-5.

References

Murialdo G, Nobili F, Rollero A, Gianelli M, Copello F, Rodriguez G . Hippocampal perfusion and pituitary-adrenal axis in Alzheimer's disease. Neuropsychobiology. 2000; 42(2):51-7. DOI: 10.1159/000026672. View

de Andrade J, Cespedes I, Abrao R, Dos Santos T, Diniz L, Britto L . Chronic unpredictable mild stress alters an anxiety-related defensive response, Fos immunoreactivity and hippocampal adult neurogenesis. Behav Brain Res. 2013; 250:81-90. DOI: 10.1016/j.bbr.2013.04.031. View

Ising M, Kunzel H, Binder E, Nickel T, Modell S, Holsboer F . The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(6):1085-93. DOI: 10.1016/j.pnpbp.2005.03.014. View

Keck M, Welt T, Muller M, Uhr M, Ohl F, Wigger A . Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology. 2003; 28(2):235-43. DOI: 10.1038/sj.npp.1300040. View

Hansson P, Murison R, Lund A, Hammar A . Cognitive functioning and cortisol profiles in first episode major depression. Scand J Psychol. 2015; 56(4):379-83. DOI: 10.1111/sjop.12230. View

Ritsner M, Strous R . Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J Psychiatr Res. 2009; 44(2):75-80. DOI: 10.1016/j.jpsychires.2009.07.002. View

Miller G, Cole S . Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry. 2012; 72(1):34-40. PMC: 3493164. DOI: 10.1016/j.biopsych.2012.02.034. View

Schatzberg A, Rothschild A, Langlais P, BIRD E, Cole J . A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res. 1985; 19(1):57-64. DOI: 10.1016/0022-3956(85)90068-8. View

Mailliet F, Qi H, Rocher C, Spedding M, Svenningsson P, Jay T . Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors: implication of MEK signaling. Exp Neurol. 2008; 211(2):593-6. DOI: 10.1016/j.expneurol.2008.02.030. View

10.

Maldonado R, Cabanero D, Martin-Garcia E . The endocannabinoid system in modulating fear, anxiety, and stress . Dialogues Clin Neurosci. 2020; 22(3):229-239. PMC: 7605023. DOI: 10.31887/DCNS.2020.22.3/rmaldonado. View

11.

Raison C, Rutherford R, Woolwine B, Shuo C, Schettler P, Drake D . A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2012; 70(1):31-41. PMC: 4015348. DOI: 10.1001/2013.jamapsychiatry.4. View

12.

Miller A . Beyond depression: the expanding role of inflammation in psychiatric disorders. World Psychiatry. 2020; 19(1):108-109. PMC: 6953590. DOI: 10.1002/wps.20723. View

13.

Engeland W, Arnhold M . Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine. 2006; 28(3):325-32. DOI: 10.1385/ENDO:28:3:325. View

14.

Herman J, Figueiredo H, Mueller N, Ulrich-Lai Y, Ostrander M, Choi D . Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol. 2003; 24(3):151-80. DOI: 10.1016/j.yfrne.2003.07.001. View

15.

Maas D, Valles A, Martens G . Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry. 2017; 7(7):e1171. PMC: 5538118. DOI: 10.1038/tp.2017.138. View

16.

Hill M, McLaughlin R, Morrish A, Viau V, Floresco S, Hillard C . Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2009; 34(13):2733-45. PMC: 3197779. DOI: 10.1038/npp.2009.114. View

17.

Zoubovsky S, Hoseus S, Tumukuntala S, Schulkin J, Williams M, Vorhees C . Chronic psychosocial stress during pregnancy affects maternal behavior and neuroendocrine function and modulates hypothalamic CRH and nuclear steroid receptor expression. Transl Psychiatry. 2020; 10(1):6. PMC: 7026416. DOI: 10.1038/s41398-020-0704-2. View

18.

Sun H, Kennedy P, Nestler E . Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology. 2012; 38(1):124-37. PMC: 3521990. DOI: 10.1038/npp.2012.73. View

19.

Chang P, Hao L, Offermanns S, Medzhitov R . The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014; 111(6):2247-52. PMC: 3926023. DOI: 10.1073/pnas.1322269111. View

20.

Pace T, Spencer R . Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor. Am J Physiol Endocrinol Metab. 2005; 288(6):E1082-8. DOI: 10.1152/ajpendo.00521.2004. View